Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Clinical trial NCT02077881 · COMPLETED
Trial details
- NCT number
- NCT02077881
- Sponsor
- NewLink Genetics Corporation
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-08-01
- Primary completion
- 2018-01-17
- Enrollment
- 157
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.